| 摘要 |
A combined pharmaceutical preparation comprising a pharmaceutically acceptable compound which binds to immunophilin and/or inhibits calcineurin- or RAFT and a pharmaceutically acceptable blood-brain barrier transport enhancer is useful for the treatment of neurodegenerative diseases and inflammatory and traumatic nervous injury. |
